Analyzing the Mechanistic Basis of Ritlecitinib's Therapeutic Effects in Alopecia Areata

Ritlecitinib (Ritle) is effective in treating severe Alopecia Areata (AA) by inhibiting JAK3 and TEC kinases, which are involved in T-cell activity. The study confirmed that Ritle reduces inflammatory cytokines and cytotoxic mediators in AA-affected skin, as well as decreases the proliferation of CD3+ T cells and the presence of CD8+GzmB+ cells in hair follicle regions. Ritle treatment also prevents immune privilege collapse and modulates immune mechanisms by reducing key pathogenic cytotoxic and resident memory T cell numbers. These findings highlight the active role of JAK3/TEC signaling in AA and Ritle's therapeutic impact on immune responses in AA patients.